



60	8 - a
10	AD
-p.5.	

EDGEWOOD ARSENAL TECHNICAL REPORT

EB-TR-76115

THE EFFECT OF INTRAVENOUS THIAMINE HYDROCHLORIDE ON PRALIDOXIME PHARMACOKINETICS IN MAN

by

John Josselson, M.D., MAJ, MC Frederick R. Sidell, M.D.

Biomedical Laboratory

December 1976





a se there was the second of

DEPARTMENT OF THE ARMY Headquarters, Edgewood Arsenal Aberdeen Proving Ground, Maryland 21010

Approved for public release; distribution unlimited.

Disclaimer

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

Disposition

when the series

and an and the A. C. it has been

Destroy this report when it is no longer needed. Do not return it to the originator.

CONTRACT OR GRANT NUMBER(*) PROGRAM ELEMENT, PROJECT, T/ Aug TA-Sep 74 g CONTRACT OR GRANT NUMBER(*) PROGRAM ELEMENT, PROJECT, T/ AREA & WORK UNIT NUMBERS IW762711/AD2502 REPORT DATE December 1976 NUMBER OF PAGES 17 SECURITY CLASS. (of this report) UNCLASSIFIED DECLASSIFICATION/DOWNGRADIN SCHEDULE N/A
Contract or grant number(*) PROGRAM ELEMENT, PROJECT, T AREA & WORK UNIT NUMBER(*) PROGRAM ELEMENT, PROJECT, T AREA & WORK UNIT NUMBERS IW762719AD2502 REPORT DATE December 1976 NUMBER OF PAGES 17 SECURITY CLASS. (of this report) UNCLASSIFIED DECLASSIFICATION/DOWNGRADIN SCHEDULE N/A
Aug M - Sep 74 - EAFORMUNG COVE Contract or grant number(*) PROGRAM ELEMENT, PROJECT, T/ AREA & WORK UNIT NUMBERS IW762710AD2502 REPORT DATE December 1976 NUMCLASSIFIED DECLASSIFICATION/DOWNGRADIN SCHEDULE N/A
Contract or grant number(*) PROGRAM ELEMENT, PROJECT, T/ AREA & WORK UNIT NUMBER(*) IW762718AD2502 REPORT DATE December 1976 NUMBER OF PAGES 17 SECURITY CLASS. (of this report) UNCLASSIFIED DECLASSIFICATION/DOWNGRADIN SCHEDULE N/A
Aug M - Sep 74 2 EARCOMMING CRO. REPORT NUMBER CONTRACT OR GRANT NUMBER() PROGRAM ELEMENT, PROJECT, T/ AREA & WORK UNIT NUMBERS IW762710AD2502 REPORT DATE Decomber 1976 NUMBER OF PAGES 17 SECURITY CLASS. (of this report) UNCLASSIFIED DECLASSIFICATION/DOWNGRADIN SCHEDULE N/A
CONTRACT OR GRANT NUMBER(*) PROGRAM ELEMENT, PROJECT, T/ AREA & WORK UNIT NUMBER(*) IW762716AD2502 REPCRT DATE December 1976 NUMBER OF PAGES 17 SECURITY CLASS. (of this report) UNCLASSIFIED DECLASSIFICATION/DOWNGRADIN SCHEDULE N/A
CONTRACT OR GRANT NUMBER(*) PROGRAM ELEMENT, PROJECT, T/ AREA & WORK UNIT NUMBERS IW762711/AD2502 REPCRT DATE December 1976 NUMBER OF PAGES 17 SECURITY CLASS. (of this report) UNCLASSIFIED DECLASSIFICATION/DOWNGRADIN SCHEDULE N/A
PROGRAM ELEMENT, PROJECT, T AREA & WORK UNIT NUMBERS IW762719AD2502 REPORT DATE December 1976 NUMBER OF PAGES 17 SECURITY CLASS. (of this report) UNCLASSIFIED DECLASSIFICATION/DOWNGRADIN SCHEDULE N/A
PROGRAM ELEMENT, PROJECT, TAREA & WORK UNIT NUMBERS IW762710AD2502
PROGRAM ELEMENT, PROJECT, TAREA & WORK UNIT NUMBERS IW762710AD2502
PROGRAM ELEMENT, PROJECT, TAREA & WORK UNIT NUMBERS IW762719AD2502 REPCRT DATE December 1976 NUMBER OF FAGES 17 SECURITY CLASS. (of this report) UNCLASSIFIED DECLASSIFICATION/DOWNGRADIN SCHEDULE N/A
IW762718AD2502
IW7627 MAD25 02 REPORT DATE December 1976 NUMBER OF PAGES 17 SECURITY CLASS. (of this report) UNCLASSIFIED DECLASSIFICATION/DOWNGRADIN SCHEDULE N/A
REPORT DATE December 1976 NUMBER OF PAGES 17 SECURITY CLASS. (of this report) UNCLASSIFIED DECLASSIFICATION/DOWNGRADIN SCHEDULE N/A
December 1976 NUMBER OF PAGES 17 SECURITY CLASS. (of this report) UNCLASSIFIED DECLASSIFICATION/DOWNGRADIN SCHEDULE N/A
DECLASSIFICATION/DOWNGRADIN SCHEDULE N/A
17 SECURITY CLASS. (of this report) UNCLASSIFIED DECLASSIFICATION/DOWNGRADIN SCHEDULE N/A
SECURITY CLASS. (of this report) UNCLASSIFIED DECLASSIFICATION/DOWNGRADII SCHEDULE N/A
UNCLASSIFIED DECLASSIFICATION/DOWNGRADII SCHEDULE N/A
DECLASSIFICATION/DOWNGRADI
N/A N/A
N/A port)
Agents
1

and the state of the second second the state of the second

7 KB

PREFACE

The work described in this report was authorized under Project/Task No. 1W762710AD25-02, Medical Defense Against Chemical Agents, Prophylaxis and Therapy for Lethal Agents. This work was started in August 1974 and completed in September 1974.

The volunteers in these tests are enlisted US Army personnel. These tests were governed by the principles, policies, and rules for medical volunteers as established in AR 70-25 and the Declaration of Helsinki.

The use of trade names in this report does not constitute an official endorsement or approval of the use of such commercial hardware or software. This report may not be cited for purposes of advertisement.

Reproduction of this document in whole or in part is prohibited except with permission of the Commander, Edgewood Arsenal, Attn: SAREA-TS-R, Aberdeen Proving Ground, Maryland 21010; however Defense Documentation Center and the National Technical Information Service are authorized to reproduce the document for US Government purposes.



CONTENTS

PRECEDING PAGES PLANK, NOT FILMED

-st. - 1

3-

		Page
I.	INTRODUCTION	5
II.	EXPERIMENTAL	5
	A. Subjects	5
	B. Design	5
	C. Controls	6
	D. Thiamine Treatment	6
	E. Calculations	6
	F. Complications	7
111.	RESULTS	7
	A. Clinical Findings	7
	B. Plasma Concentration	7
	C. Urinary Excretion of Pralidoxime	7
	D. Renal and Plasma Clearance	8
IV.	KINETIC DATA	8
	A. Volumes of Distribution	8
	B. Plasma Half-Life	12
	C. Equilibrium Constants	12
v.	DISCUSSION	12
	LITERATURE CITED	14
	DISTRIBUTION LIST	15

and the second second the second second second

THE EFFECT OF INTRAVENOUS THIAMINE HYDROCHLORIDE ON PRALIDOXIME PHARMACOKINETICS IN MAN

I. INTRODUCTION

Pralidoxime chloride (pyridine-2-aldoxime methochloride)*, an adjunct to atropine in the treatment of anticholinesterase intoxication, is rapidly and almost completely (80-90%) excreted in the urine¹⁻⁶. This necessitates frequent administration in those circumstances in which a prolonged plasma concentration is desirable.

Swartz et al.,⁵ recently reported that concurrent intramuscular administration of thiamine hycrochloride with intravenous pralidoxime prolongs plasma half-life and delays the renal elimination of oxime. This suggests that pralidoxime might be handled by the kidney as a strong organic base and might be secreted by the same mechanism by which other strong bases (e.g., thiamine, choline, guanidine, tetraethylammonium) are secreted. Thus, concurrent administration of two bases competing for the same mechanism might lead to delayed secretion of one or both⁷.

Those results led us to explore further the clinical use of thiamine hydrochloride to potentiate plasma oxime levels. This report describes the pharmacokinetics of pralidoxime when administered one hour after the start of a continuous infusion of thiamine hydrochloride.

II. EXPERIMENTAL

A. Subjects.

The subjects were US Army enlisted men who agreed to the protocol after thorough explanation and discussion. Screening included complete physical and laboratory examinations**. A detailed history of allergy was obtained and intradermal scratch testing with thiamine was performed to exclude potentially hypersensitive subjects. All scratch tests were negative; two potential subjects were excluded from the study on the basis of a strongly atopic history.

B. Design.

a can black the Kill of the "the

Six subjects participated and received pralidoxime with and without thiamine, each serving as his own control. Subjects entered the ward on the evening before the study, ate a light breakfast about one hour before the study began, and drank about 1 to 2 liters of fluid in the two hours prior to testing. Each subject was tested at one-week intervals in a randomized crossover design plan.

^{*}Protopam^R, Ayerst Laboratories, New York, NY 10017.

^{**}Chest X-ray, ECG, complete blood count, routine urinalysis, blood urea nitrogen, serum creatinine, liver function tests (SGOT, alkaline phosphatase, serum bilirubin).

C. Controls.

At the start of testing, a continuous infusion of normal saline into the anticubital vein was begun and continued for 2.5 hours. One hour after the infusion was started, each subject received an intravenous injection of 5 mg/kg of pralidoxime chloride over two minutes through the scalp needle of the infusion line.

D. Thiamine Treatment.

At the start of testing, a continuous infusion containing normal saline and thiamine hydrochloride^{*} was begun; thiamine was delivered at a rate of 100 mg/hr over 2.5 hours (2.0 mg thiamine/ml normal saline, 50 ml/hr). One hour after the infusion was begun, each subject received an iv injection of pralidoxime, 5 mg/kg, as in the control trial.

Urine from each subject was pooled for the following periods: 0-1.5, 1.5-3, 3-6, and 6-24 hours. Urine was collected for an additional 12 hours from four thiamine-treated subjects. Plasma specimens were obtained through an indwelling scalp needle in a vein in the opposite arm, kept open with heparin, at 0.05, 0.10, 0.15, 0.25, 0.50, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, and 4.0 hours after the injection of oxime. Plasma and urine were analyzed by the method of Groff *et al.*⁸ for oxime. Pulse and blood pressure, and subjective responses to both thiamine and pralidoxime, were closely monitored. Subjects were kept in bed during the 2.5-hour infusion; then they were allowed to walk around.

E. Caiculations.

A BAR ALLE THE ALL AND A DE ALLE AND A

The serial plasma oxime concentrations plotted against time fit the curve described by the bi-exponential equation¹

$$C = Ae^{-\alpha t} + Be^{-\beta t}$$
(1)

which describes the disposition of drug in a two-compartment model. In this equation, C is the plasma concentration, t is the time, A and B represent the zero-time intercepts of the linear components of the rapid and slow portions of the plasma decay curve, and α and β represent the slopes of these two lines divided by -2.303. A more detailed description of the derivation of this equation is provided by Wagner⁹ and discussed with respect to pralidoxime in studies by Swartz *et al.*^{4,5} and Sidell¹. The computer program NONLIN¹⁰ was used to estimate the parameters of this equation. From them the following were calculated:

1. The half-life of the rapid equilibrium phase $(t_{1/2\gamma})$ and the slower elimination phase $(t_{1/2\beta})$.

2. The volumes of distribution of the central compartment (V_1) , the peripheral compartment (V_2) , and the total volume (V_d) .

^{*}Thiamine Hydrochloride Injection U.S.P. 10 mg/cc, Natcon Chemical Co., Inc., Plainview, NY.

3. The rate constants for drug movement from central to peripheral compartment (K_{12}) , from peripheral to central compartment (K_{21}) , and for elimination from the central compartment (K_{13}) .

4. The plasma and renal clearances of pralidoxime.

The plasma clearance was calculated by dividing the dose of pralidoxime by the area under the plasma concentration versus time curve (which was obtained from the integral of equation 1); the renal clearance was obtained by dividing the amount of pralidoxime excreted into the urine during a given time period by the area under the curve of that time interval.

F. Complications.

Because of difficulties encountered during administration of oxime to two thiamine-treated subjects, rapid intravenous infusion was not achieved; hence, plasma data on only four thiamine-treated subjects were used for calculations of the parameters listed above compared to control data from six subjects.

Likewise, loss of one urine specimen (1.5-3 hours) from one control subject prevented calculating each parameter.

III. RESULTS

in a second the state of the state

A. Clininal Findings.

Both thiamine and pralidoxime were well tolerated by all subjects. No objective or subjective changes were noted after initiation of thiamine infusion. Following pralidoxime, all subjects complained of mild-to-moderate visual symptoms characterized as "blurring" or visual heaviness, lasting five to 10 minutes. Tests of extraocular muscle movement, accommodation, and light reflex were normal in all men. No changes in blood pressure or pulse rate were noted following oxime injection. Intravenous injection of thiamine did not potentiate any of the subjective experiences and did not alter pulse rate and blood pressure after oxime was given.

B. Plasma Concentration (Six Control Subjects; Four Thiamine-Treated Subjects).

The mean plasma concentrations of pralidoxime are plotted in the following figure. After six minutes, the plasma concentrations of the thiamine-treated group were significantly higher than those of the control group (p < 0.05; paired t test) at each time interval during the remaining hours of blood sampling.

C. Urinary Excretion of Pralidoxime.

Over the 24-hour period of urine collection, there was no significant difference in total oxime excretion between the control group and thiamine-pretreated groups. The former excreted 85.7% (±6.2 S.D., n=5) and the latter 87.2% (±5.2, n=6) of the injected pralidoxime. However, in the first 1.5 hours the thiamine-treated men eliminated significantly less oxime

(38.2% vs 72.4% of the total 24-hour urinary oxime excretion, p < 0.001, paired t test, n=5) than the subjects in the control group and, in the remaining 22.5 hours, significantly more (46.3% vs 12.8%, p < 0.01, paired t test, n=5) (table 1).



Figure. Mean Plasma Concentrations of Pralidoxime

D. Renal and Plasma Clearance.

Mean renal and plasma clearance data are presented in table 2. The renal clearance of oxime at 1.5 hours was significantly reduced by the simultaneous administration of thiamine (p < 0.01, paired t test, n=4), and this maintained over 24 hours. Similarly, the plasma clearance of pralidoxime was greatly reduced by the administration of thiamine (p < 0.01, paired t test, n=4).

IV. KINETIC DATA

and see the with the second

The kinetic data are shown in table 3.

A. Volumes of Distribution.

Following thiamine administration, there was a definite decrease in the total volume of distribution (p < 0.05, paired t test, n=4), characterized by a large decrease in the peripheral (extravascular) volume, V_2 (p < 0.05), and a moderate increase in the central compartment (p < 0.05).

Table 1. Urinary Recovery of Pralidoxime

Dungta	Control	P Thiamine	Р	1
0-1.5 hr	72.4 ± 3.3	38.2 ± 9.0	<.001	-
0-3 hr	87.2 ± 2.4	53.7 ± 4.2	<.01	84
0-6 hr	97.0 ± 1.0	75.9 ± 8.6	<.01	00
0-24 hr	100	100	513	

(a) Mean Cumulative Excretion of Pralidoxime Over 24 Hours*

* Expressed as percent of the total amount of pralidoxime excreted in the urine ±S.D.

	Control	P Thiamine	Р
0-1.5 hr	72.4 ± 3.3	38.2 ± 9.0	<.001
1.5-3 hr	14.8 ± 2.4	15.5 ± 2.1	>.70
3-6 hr	9.8 ± 2.1	22.2 ± 2.2	<.01
6-24 hr	3.0 ± 1.0	24.1 ± 8.6	<.01
Total	100	100	-

あたいろうい

a se west to the total and the

(b) Mean Urinary Excretion of Pralidoxime for Each Collection Period

Case	Renal cl	earance	Renal cle	arance	Plass	na
number	at 1.5 c*	t**	at 24 fi	t**	cteara	t**
6731	477	1997 - 1997 718-1	437		548	
6748	502	- 1	527	<u>_</u> ****	631	- 20
6736	546	109	535	253	565	293
6717	515	132	496	216	536	286
6718	574	245	-	441	726	489
6730	717	283	848	350	741	385
Mean	555	205	529	315	625	363
S.D. ±	86.23	97.86	77.06	101.2	90.71	95.20
P†	<0	.01	<0.0	01	<0.0	01
n			3		4	

Table 2. Renal and Plasma Clearances (ml/min)

* Oxime alone ** Oxime and Thiamine [†] Paired t test

and the second of the second the second the second se

				NUD I	0. FIId	IIIIacon		and and a				
Case	A (µg/ml)	α (hr ⁻¹)	B (µg/ml)	e (hr ⁻¹)	t ½a (hr)	t ½3 (hr)	K21 (hr ⁻¹)	K ₁₃ (hr ⁻¹)	$\overset{K_{12}}{^{(hr^{-1})}}$	V ₁ (ml/kg)	V ₂ (ml/kg)	VD (ml/kg)
					01	CONTR	리					
6731	29.0	9.8	5.4	0.53	0.07	1.30	1.99	2.61	5.69	145	415	560
6748	21.2	11.9	5.8	0.79	0.059	0.88	3.15	2.96	6.53	185	385	570
6736	23.3	8.3	4.6	0.51	0.083	1.25	1.83	2.52	4.52	179	443	622
6717	26.8	10.1	8.1	0.66	0.069	1.05	2.83	2.34	5.56	143	281	425
6718	19.3	9.6	4.7	0.61	0.072	1.14	2.38	2.47	5.38	208	470	678
6730	17.5	10.1	4.4	0.66	0.069	1.05	2.56	2.59	5.57	228	496	
Mean	22.9	10.0	5.5	0.63	0.070	1.11	2.46	2.56	5.54	182	415	597
S.D. ±	4.4	1.1	1.4	60.0	0.01	0.15	0.50	0.21	0.64	33.7	76.5	105
						-						
					THIAN	AINE-T	REATEL					
6731												
6748												
6736	9.8	3.8	8.7	0.47	0.18	1.46	2.08	0.86	1.36	268	175	443
6717	14.0	6.1	10.8	0.42	0.11	1.64	2.87	0.89	2.71	202	191	393
6718	12.4	4.1	5.5	0.47	0.17	1.46	1.59	1.23	1.79	280	319	594
6730	15.7	4.8	5.4	0.42	0.14	1.63	1.53	1.32	2.35	238	364	109
Mean	13.0	4.7	7.6	0.45	0.15	1.55	2.02	1.08	2.05	247	261	508
S.D. ±	2.5	1.0	2.7	0.03	0.03	0.10	0.62	0.23	09.0	34.7	0.924	105.6
*d	0.05	0.001	N3	0.05	0.01	0.02	N3	0.001	0.001	0.05	0.05	0.05
				1	1	1	1					

ā

the second as a court the Art with the second

* By paired t test N = 4

B. Plasma Half-Life.

Following thiamine administration, significant increases occurred in both the short half-time, t $1/2\gamma$ (0.07 hr vs 0.15 hr, p < 0.01, n=4) and, more importantly, the long half-life of elimination, t $1/2\beta$ (1.11 hr vs 1.55 hr, p < 0.02, n=4).

C. Equilibrium Constants.

Likewise, following thiamine, highly significant decreases occurred in the rate constants K_{12} (p < 0.001, n=4) and K_{13} (p < 0.001, n=4). The change in K_{12} closely parallels the decrease in the peripheral compartment noted above.

V. DISCUSSION

These data indicate that concurrent intravenous administration of thiamine hydrochloride significantly decreases both the renal and plasma clearance and delays the renal elimination of pralidoxime chloride apparently without altering the mode of excretion. Such treatment was associated with substantially higher plasma concentrations of oxime than in the controls throughout the 4-hour period of blood sampling. This study extends the investigation of Swartz *et al.*⁵ (who administered thiamine intramuscularly with the oxime) by intravenous pretreatment with the vitamin to achieve and maintain maximal plasma levels at the time of oxime administration.

A dose of 100 mg of thiamine per hour was empirically selected for the pretreatment dose. Neither pharmacokinetic data nor renal tubular secretory transport maxima are available for thiamine, and it is possible that still larger doses of the vitamin would further retard the renal elimination of oxime.

During the 1.5 hours of thiamine administration after injection of pralidoxime, the amount of oxime excreted in the urine was halved. This suggests that prolonging the thiamine infusion at the same rate might have maintained this difference for a longer period of time.

The fractional recovery of oxime in the urine, the plasma half-life for elimination, and the renal and plasma clearances of the drug noted are comparable to those noted previously ^{1,5}. Swartz⁵, however, reported no significant changes in volumes of distribution after intramuscular thiamine administration, though a tendency did appear toward a reduction in the peripheral compartment $(V_2)^*$. In contrast, our data show significant changes in all those volumes (table 3). A definite explanation for this phenomenon is not possible, but the alternatives include: (1) increased protein binding affinity for oxime following thiamine administration (but since pralidoxime is negligibly bound, this seems unlikely); (2) increased sequestration of pralidoxime by other organs (e.g., CNS, liver); and (3) alteration of erythrocytic and/or vascular membrane permeabilities by as yet unknown mechanisms.

*Personal communication.

and it was thank to at the work of

While this study does not offer proof, these data suggest that pralidoxime may be excreted, at least in part, by a renal secretory mechanism shared by several other strong organic bases⁷ although this does not exclude the possibility that several different mechanisms may be involved in the renal elimination of oxime. Ultimate identification of the responsible mechanism will depend upon further studies with specific blockers of secretion and reabsorption as well as the use of micropuncture techniques.

The effect of thiamine in prolonging the plasma half-life of pralidoxime has been demonstrated, although the clinical value of this regimen in the therapy of anticholinesterase poisoning has not been investigated. Thiamine appears well tolerated in pharmacologic doses and has an extremely low incidence of undesirable side effects; however, a few case reports indicate that a rare but fatal allergic reaction to parenteral (particularly intravenous) administration of thiamine may occur and is presumably anaphylactic¹¹⁻¹³.

These results suggest that larger doses of thiamine might produce even larger increases in the half-life of pralidoxime, and it is possible that other strong organic bases with quaternary N^+ sites – such as guanidine, choline, and tetraethylammonium – might be equally effective. Additional studies are currently under way.

A. Sulley

and share the states the

W Lobert Laborato

givila.

sytu ?

 $(1 \circ 1)$

1.2 706.2

a war thank the state of the

1962.

Li for NONEIN. 11.

South Anna Martin

an entropy of

LITERATURE CITED

1. Sidell, F. R., Groff, W. A., and Kaminskis, A. Toxogonin and Pralidoxime: Kinetic Comparison After Intervenous Administration to Man. J. Pharm, Sci., 61, 1765-9 (November 1972).

2. Kondritzer, A. A., Zvirblis, P., Goodman, A., and Paplanus, S. H. Blood Plasma Levels and Elimination of Salts of 2-PAM in Man After Oral Administration. J. Pharm. Sci., 57, 1142-6, (July 1968).

3. Loomis, T. A. Distribution and Excretion of Pyridine-2-aldoxime Methodide (PAM); Atropine and PAM in Sarin Poisoning. Toxicol. and Appl Pharmacol., 5, 489-99 (1963).

4. Swartz, R. D., and Sidell, F. R. Effects of Heat and Exercise on the Elimination of Pralidoxime in Man. Clin. Pharm. Ther., 14, 83-89 (1973).

5. Swartz, R. D., and Sidell, F. R. Renal Tubular Secretion of Pralidoxime in Man. Edgewood Arsenal Technical Report EB-TR-73017. January 1974. UNCLASSIFIED report.

6. Berglund, F., Elwin, D. E., and Sundwall, A. Studies on the Renal Elimination of N-methyl-pyridinium-2-aldoxime. Biochem. Pharmacol., 2,383-388 (1962).

7. Peters, L. Renal Tubular Excretion of Organic Bases. Pharmacol. Rev., 12, 1-35 (1960).

8. Groff, W. A., and Ellin, R. J. A New and Rapid Determination of Pyridinium Aldoximes in Blood and Urine. Clin. Chem. 15, 72-83 (1962).

9. Wagner, J. C. Pharmacokinetics. J. M. Richard Laboratories, Grosse Pointe, Michigan. 1969.

10. Metzler, C. M. A User's Manual for NONLIN. The Upjohn Company. November 25, 1969.

11. Smith, J. A., Fo, P. P., Weinstein, H. R., Ludwig, A. S., and Weitherion, J. M. Some Aspects of Thiamine Toxicity. J. Pharm. Exp. Ther., 93, 294-304 (July 1948).

12. Haley, T. J., and Flesher, A. M. A Toxicity Study of Thiamine Hydrochloride. Science, 104, 567-8 (December 1946).

13. Reingold, J. M., and Webb, F. R. Sudden Death Following Intravenous Injection of Thiamine Hydrochloride. J.A.M.A., 130, 491-2 (1946).

and a san tened that the to be started

DISTRIBUTION LIST 4

Copies

1

1

1

1

1

1

2

7

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

2

3

1

12

Names

EDGEWOOD ARSENAL

FOREIGN INTELLIGENCE OFFICER CHIEF, LEGAL OFFICE CHIEF, SAFETY OFFICE CHIEF, PLANS OFFICE Attn: SAREA-PL CDR, US ARMY TECHNICAL ESCORT CENTER PUBLIC HEALTH SERVICE LO AUTHOR'S COPY, Biomedical Laboratory

BIOMEDICAL LABORATORY Attn: SAREA-BL-M Attn: SAREA-BL-O Attn: SAREA-BL-Q Attn: SAREA-BL-R Attn: SAREA-BL-RC Attn: SAREA-BL-RE Attn: SAREA-BL-RI Attn: SAREA-BL-V

CHEMICAL LABORATORY Attn: SAREA-CL Attn: SAREA-CL-B Attn: SAREA-CL-BS Attn: SAREA-CL-BS Attn: SAREA-CL-D Attn: SAREA-CL-D Attn: SAREA-CL-P Attn: SAREA-CL-TE

DEVELOPMENT AND ENGINEERING DIRECTORATE Attn: SAREA-DE-D Attn: SAREA-DE-EP Attn: SAREA-DE-ET Attn: SAREA-DE-M Attn: SAREA-DE-N

MANUFACTURING TECHNOLOGY DIRECTORATE Attn: SAREA-MT-D Attn: SAREA-MT-E Attn: SAREA-MT-P

DIRECTOR OF PRODUCT ASSURANCE Attn: SAREA-PA-A Attn: SAREA-PA-P Attn: SAREA-PA-Q

DIRECTOR OF TECHNICAL SUPPORT Attn: SAREA-TS-R Attn: SAREA-TS-L Attn: SAREA-TS-E

DEPARTMENT OF DEFENSE

Administrator Defense Documentation Center Attn: Accessions Division Cameron Station Alexandria, VA 22314

Names

Director Defense Intelligence Agency Attn: DB-4G1 Washington, DC 20301

DEPARTMENT OF THE ARMY

HQDA (DAMO-SSC) WASH DC 20310

Director Defense Civil Preparedness Agency Attn: RE Attn: PO(DC) Washington, DC 20301

CINCUSAREUR Attn: AEAGC-DS APO New York 09403

Chief, Office of Research, Development & Acquisition Attn: DAMA-CSM-CM Attn: DAMA-ARZ-D Washington, DC 20310

Headquarters, Sixth US Army NBC Office Attn: AFKC-OP-PN Presidio of San Francisco, CA 94129

HQDA (DAMI-FIT) WASH, DC 20310

CINCUSAREUR Attn: AEAMD-PM APO New York 09403

US ARMY HEALTH SERVICE COMMAND

Commander US Army Environmental Hygiene Agency Attn: HSE-AA-L, Librarian, Bldg 2100 APG-Edgewood Area

Superintendent Academy of Health Sciences US Army Attn: HSA-CDC Attn: HSA-IHE Fort Sam Houston, TX 78234

OFFICE OF THE SURGEON GENERAL

HQDA (SGRD-HR) Forrestal Building WASH DC 20314 Copies

1

1

1

1

1

1

1

1

DISTRIBUTION LIST 4 (Contd)

Names

READINESS COMMAND

Copies

1

1

1

2

1

1

1

US ARMY MATERIEL DEVELOPMENT AND

Commander US Army Materiel Development and Readiness Command Attn: DRCDE-DM Attn: DRCLDC Attn: DRCMT Attn: DRCSF-S 5001 Eisenhower Ave Alexandria, VA 22333

Commander US Army Foreign Science & Technology Center Attn: DRXST-IS1 220 Seventh St., NE Charlottesville, VA 22901

Project Manager for Chemical Demilitarization and Installation Restoration Attn: DRCPM-DR, Bldg E4585 APG-Edgewood Area

Redstone Scientific Information Center Attn: Chief, Documents US Army Missile Command Redstone Arsenal, AL 35809

Director DARCOM Field Safety Activity Attn: DRXOS-C Charlestown, IN 47111

US ARMY ARMAMENT COMMAND

Commander US Army Armament Command Attn: DRSAR-ASN Attn: DRSAR-IMB-C Attn: DRSAR-RDM Attn: DRSAR-RDT Rock Island, IL 61201

Commander US Army Dugway Proving Ground Attn: Technical Library, Docu Sect Dugway, UT 84022

Commander Rocky Mountain Arsenal Attn: SARRM-EA Attn: SARRM-MD Denver, CO 80240

and a fer thank the share the state

Commander Pine Bluff Arsenal Attn: SARPB-ETA Pine Bluff, AR 71611

Names

US ARMY TRAINING & DOCTRINE COMMAND

Commandant US Army Infantry School Combat Support & Maintenance Dept. Attn: NBC Division Fort Benning, GA 31905

Commandant US Army Missile & Munitions Center & School Attn: ATSK-CD-MD Attn: ATSK-DT-MU-EOD Redstone Arsenal, AL 35809

Commandant US Army Military Police School Attn: ATZN-CD Fort McClellan, AL 36205

Chief, Training Literature Division Attn: ATZN-TDP Fort McClellan, AL 36205

Headquarters US Army Military Police School/Training Center Attn: ATSJ-TD-CR Fort McClellan, AL 36205

Commander US Army Infantry Center Attn: ATZB-CD-MS-C Fort Benning, GA 31905

Commandant US Army Ordnance Center & School Attn: ATSL-CD-MS Attn: ATSL-DTG APG-Aberdeen Area

US ARMY TEST & EVALUATION COMMAND

Record Copy CDR, APG Attn: STEAP-AD-R/RHA APG-Edgewood Area, Bldg E5179 de la

Copies

1

1

1

1

1

1

1

DISTRIBUTION LIST 4 (Contd)

Names	Copies	Names	Cop
CDR, APG		Chief, Bureau of Medicine & Surgery	
Attn: STEAP-TL	1	Department of the Navy	
APG-Aberdeen Area		Attn: CODE 5	1
		Washington, DC 20372	
Commander			
US Army Test & Evaluation Command		Commander	
Attn: DRSTE-FA	1	Naval Weapons Center	
APG-Aberdeen Area		Attn: A. B. Galloway/Code 3171	1
		Attn: Technical Library/Code 233	1
Commander		China Lake, CA 93555	
US Army Cold Regions Test Center			
Attn: STECR-TD	1	DEPARTMENT OF THE AIR FORCE	
APO Seattle 98733			
		Air University Library	
Commander		Attn: AUL/LSE-8879	1
US Army Tropic Test Center		Maxwell AFB, AL 36112	
Attn: STETC-MO-A (Tech Library)	1		
APO New York 09827		HQ Foreign Technology Division (AFSC)	
		Attn: PDRR	1
Commander		Wright-Patterson AFB, OH 45433	
Dugway Proving Ground			
Attn: STEDP-PO	1	Commander	
Dugway, UT 84022		Aeronautical Systems Division	
		Attn: ASD/AELD	1
DEPARTMENT OF THE NAVY		Wright-Patterson AFB, OH 45433	
		NO. NO. DIGODO	
Chief of Naval Research		HQ, USAF/SGPK	1
Attn: Code 443	1	VACUE DC 20214	
SUO N. Quincy Street		WASH DC 20314	
Arlington, VA 22217			
		NU, USAF/KUPN	-
Commander		WASH DC 20330	
Naval Facilities Engineering Command			
Attn: Code 03	1	HQ, Ugden ALC/MMWRA	1
200 Stovall Street		HIII AFB, UT 84406	
Alexandria, VA 22332			
		Director	
Commander .		Air Force Inspection and Safety Center	
Naval Explosive Ordnance Disposal Facility		Attn: IGD(AFISC/SEV)	1
Attn: Army Chemical Office	1	Norton AFB, CA 92409	
indian Head, MD 20040		Commander	
Commander	1	Armament Development & Test Center	
Naval Surface Weapons Center		Attn: DLOSL (Technical Library)	-
Attn: Tech Lib & Info Svos Br	1	Eglin AFB, FL 32542	
White Oak Laboratory			
Silver Spring MD 20010		NORAD Combat Operations Center/DBN	1
stor opting, MD 20110		Cheyenne Mtn Complex, CO 80914	
Commander		OUTSIDE AGENCIES	
Naval Surface Weapons Center		OUISIDE AGENCIES	
Dahlgren Laboratory		Battelle, Columbus Laboratories	
Attn: DX-21	1	Attn: TACTEC	1
Dahlgren, VA 22448		505 King Avenue	
		Columbus, OH 43201	
Commander			
Nuclear Weapons Training Group, Atlantic		Director of Toxicology	1
Naval Air Station		National Research Council	
Attn: Code 21	1	2101 Constitution Ave, NW	
Nortolk, VA 23511		Washington DC 20418	

のないないのでいたが、

and the second second